AxoGen, Inc. (NASDAQ:AXGN) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in AxoGen, Inc. (NASDAQ:AXGN) by 34.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,763 shares of the medical equipment provider’s stock after acquiring an additional 5,576 shares during the quarter. SG Americas Securities LLC’s holdings in AxoGen were worth $359,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Geode Capital Management LLC increased its position in shares of AxoGen by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock worth $14,170,000 after purchasing an additional 31,612 shares during the last quarter. State Street Corp lifted its stake in AxoGen by 11.9% during the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock worth $12,571,000 after purchasing an additional 95,051 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in AxoGen by 2,912.3% during the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock worth $7,697,000 after purchasing an additional 530,775 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in AxoGen during the third quarter worth approximately $5,789,000. Finally, Charles Schwab Investment Management Inc. increased its position in AxoGen by 8.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 363,764 shares of the medical equipment provider’s stock worth $5,100,000 after buying an additional 28,659 shares during the period. 80.29% of the stock is owned by institutional investors and hedge funds.

AxoGen Stock Down 1.6 %

AXGN opened at $17.92 on Tuesday. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a market cap of $788.66 million, a P/E ratio of -56.00 and a beta of 1.00. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $19.06. The business’s fifty day simple moving average is $16.25 and its 200 day simple moving average is $13.88.

Analyst Ratings Changes

Several research analysts have commented on AXGN shares. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Canaccord Genuity Group increased their price objective on AxoGen from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.